Osteosarcoma

Lirum Therapeutics Presents Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers

Retrieved on: 
Monday, June 5, 2023
Neuroblastoma, Graves' ophthalmopathy, Rhabdomyosarcoma, Osteosarcoma, Alveolar rhabdomyosarcoma, IC50, Therapy, Sarcoma, News, TED, Cancer, Pharmaceutical industry

LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines of pediatric cancers with well-established IGF-1/IGF-1R pathway involvement.

Key Points: 
  • LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines of pediatric cancers with well-established IGF-1/IGF-1R pathway involvement.
  • These include cancers with known genetic alterations affecting the IGF-1/IGF-1R pathway and/or with high IGF-1R expression such as Ewing’s and related sarcomas, rhabdomyosarcoma, osteosarcoma, and neuroblastoma.
  • The audio poster presentation from the conference is available on the Lirum website (www.lirumtx.com) under the News and Events tab.
  • Given these promising results, and the existing clinical data, Lirum is planning new clinical trials with LX-101 in these indications that carry strong ties to the IGF-1/IGF-1R pathway.

Morris Animal Foundation selects 10 fellowship studies for funding

Retrieved on: 
Tuesday, May 30, 2023
Ohio State University, White-nose syndrome, Yale University, University, Fungal infection, University of Illinois Urbana-Champaign, Horse, Colorado State University, Infection, Osteosarcoma, Escherichia coli, University of California, Jagiellonian University, Biomarker, Gene expression, University of Georgia, Abdominal cavity, Urinary tract infection, Animal, Investment, Tuberculosis, Risk, Dog, Systemic inflammatory response syndrome, Blood, University of Wisconsin–Madison, Morris Animal Foundation, McIntosh, Health, Air pollution, Disease, Vaccine, Agriculture

DENVER, May 30, 2023 /PRNewswire/ -- Morris Animal Foundation announced it is funding 10 new fellowship studies, with two of the studies funded by longtime donor Sally R. McIntosh.

Key Points: 
  • DENVER, May 30, 2023 /PRNewswire/ -- Morris Animal Foundation announced it is funding 10 new fellowship studies, with two of the studies funded by longtime donor Sally R. McIntosh.
  • The studies will focus on a variety of topics, including deadly infections in dogs, immune response disorders in horses and amphibian conservation.
  • "Our Fellowship Training program is one of the most impactful investments we can make for animal health research," said Dr. Kathy Tietje, Chief Program Officer at Morris Animal Foundation.
  • McIntosh made her first gift to Morris Animal Foundation to advance greyhound health research in 2009 and since then, has expanded her support into other areas of animal health research, including wildlife health.

QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

Retrieved on: 
Tuesday, May 23, 2023
Partnership, Bone, Cancer, Osteosarcoma, OTCQB, Breast, Prostate, MD, Patient, Sarcoma, Medical Center, RLS, Nuclear pharmacy, QSAM, Medical imaging, Pharmaceutical industry

QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals. Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.

Key Points: 
  • QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, as well as assess early efficacy signals.
  • Patients with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as patients with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- may be eligible.
  • "We are pleased to be working with the excellent team at Insight Hospital and Medical Center to continue the expansion of our drug development program for CycloSam® in the large population center of Chicago,” stated Douglas R. Baum, CEO and co-founder of QSAM.
  • “Therapeutic radiopharmaceuticals like CycloSam® represent a novel and potentially important treatment option for patients suffering from this debilitating and deadly disease.”

Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

Retrieved on: 
Tuesday, May 9, 2023
PDAC, Pancreatic cancer, Drug, LRRC15, US Foods, RAD, Survival, Cancer, Osteosarcoma, Head, ASX, Lung cancer, Neck, Patient, Colorectal cancer, Orphan, Diagnosis, FDA, Carcinoma, Food, Pharmaceutical industry

Radiopharm is developing Trivehexin as a novel radiopharmaceutical for imaging and treatment of pancreatic cancer.

Key Points: 
  • Radiopharm is developing Trivehexin as a novel radiopharmaceutical for imaging and treatment of pancreatic cancer.
  • The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target.
  • “Orphan Drug Designation for RAD 301 comes on top of FDA IND approval for a Phase I clinical trial in pancreatic cancer, which is planned to start in the next few weeks in the United States,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics.
  • Designation is granted for a drug or biologic product with the potential to diagnose, prevent or treat rare diseases and conditions.

Stowers Institute scientists discover the dynamics of an "extra" chromosome in fruit flies, offers unique opportunity to study similar chromosomes linked to cancer and infertility in humans

Retrieved on: 
Thursday, May 4, 2023
University, Medicine, Human, Stowers Institute for Medical Research, Neoplasm, Drosophila melanogaster, Meiosis, Osteosarcoma, Infertility, Research, Hanlon, Fruit, Bangladesh Technical Education Board, Current Biology, Chromosome, Achilles, Cancer, Cell division, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Medical research, NIH, Biology, Genome, Dietary supplement, Antibiotics

Now, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility.

Key Points: 
  • Now, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility.
  • Previous research from the Hawley Lab had first identified these small, extra chromosomes, but little was known about their form, function, or dynamics during cell division.
  • In addition, the presence of supernumerary chromosomes in men can disrupt normal chromosome segregation during sperm production, which can cause infertility.
  • "Being able to understand how supernumerary chromosomes arise and what their structures are can potentially illuminate their vulnerabilities," said Hawley.

Petco Love Investing Additional $1 Million in the Fight Against Pet Cancer

Retrieved on: 
Tuesday, May 2, 2023
Love, Partnership, University, Amputation, Louisiana State University, Parent, Osteosarcoma, Cancer, University of Pennsylvania, University of California, Research, Leg, Thymoma, LSU, Labrador Retriever, Colorado State University, SAN, Dog, Ohio State University, Pet, Virginia Tech Foundation, School, Cat, Texas A&M University, Veterinary medicine, Death, Family, Petco, Jubal, Disease, Pet industry, Medical imaging

SAN ANTONIO, May 2, 2023 /PRNewswire/ -- Petco Love knows pets are love. Today the national nonprofit, in partnership with Blue Buffalo, is returning the love by continuing to raise awareness about pet cancer and supporting pets fighting the disease. Pet cancer impacts millions of pets every year as the number one disease-related cause of death for dogs and cats in the U.S., afflicting one in four dogs and one in five cats.

Key Points: 
  • Petco Love and Blue Buffalo are partnering for the 14th annual May Pet Cancer Campaign and recognizing the $19 million impact made together in the fight against pet cancer, furthering pet cancer research, and supporting treatment for pets in need.
  • "We know pets are family, and too many pet parents are facing the challenges a cancer diagnosis brings," said Susanne Kogut , President of Petco Love.
  • Throughout May, Petco Love and Blue Buffalo are driving awareness of pet cancer and the need for early detection, including sharing the ten warning signs of cancer in dogs and cats .
  • Anyone can also join the fight against pet cancer with Petco Love and help improve access to pet cancer treatment for pets and their families by donating at petcolove.org/pca .

QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Retrieved on: 
Wednesday, April 5, 2023
Bone, Cohort, Clinical trial, Osteosarcoma, OTCQB, Woman, Breast, Prostate, Lung, Cancer, Patient, Growth, American Cancer Society, QSAM, Safety, Breast cancer, Pharmaceutical industry, Medical imaging

“We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients,” stated Douglas R. Baum, CEO.

Key Points: 
  • “We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients,” stated Douglas R. Baum, CEO.
  • The total dosage of the active radioisotope Samarium-153 to be received by participants in the second cohort is 50% higher than the total dose received by participants in the first cohort.
  • QSAM is dedicated to developing its Cyclosam® product for this important patient population, and patients with any of these bone cancer types are eligible for this clinical trial.
  • Osteosarcoma, while still a rare pediatric disease, is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy; and Ewing’s Sarcoma bone cancer is the second most common form of bone cancer in children.

QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Retrieved on: 
Tuesday, February 28, 2023
Clinical trial, Safety, Breast cancer, Female, Cancer, Prostate cancer, Osteosarcoma, FDA, Patient, American Cancer Society, QSAM, Bone, Male, Metastasis, Breast, Woman, Sarcoma, OTCQB, Prostate, Lung, Medical imaging, Pharmaceutical industry

The last participant dosed was a breast cancer patient with active metastatic bone cancer.

Key Points: 
  • The last participant dosed was a breast cancer patient with active metastatic bone cancer.
  • The only two commercially available radiotherapies for bone cancer, to management’s knowledge, are only FDA-approved for use in men who have bone metastases from prostate cancer.
  • Adults with bone cancer that has migrated or metastasized from the breast, lung or prostate is common and frequently fatal.
  • Osteosarcoma, while still a rare pediatric disease, is the most common form of bone cancer in children and young adults (ages 15-39) with primary high-grade bone malignancy, and Ewing’s Sarcoma bone cancer is the second most common form of bone cancer in children.

QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer

Retrieved on: 
Wednesday, February 22, 2023
Clinical trial, Safety, American College, School, III, Ellis Fischel Cancer Center, EFCC, MD, University, Osteosarcoma, Translational research, Associate, American College of Surgeons, American Cancer Society, QSAM, Bone, Commission, MU, Clinical Science (journal), Breast, Radiation, SOM, Sarcoma, Dean (education), OTCQB, Prostate, Lung, Pharmaceutical industry, Medical imaging, Cancer

QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in participants, and also assess early efficacy signals. Participants with bone cancer that has metastasized from the breast, lungs, prostate or other organs, as well as participants with cancer that has originated in the bone such as osteosarcoma and Ewing’s Sarcoma – diseases that mostly affect children and young adults -- are also eligible subject to the trial’s inclusion and exclusion criteria.

Key Points: 
  • The Ellis Fischel Cancer Center is accredited as an Academic Comprehensive Cancer Program by the Commission on Cancer, an American College of Surgeons quality program.
  • Ellis Fischel is QSAM’s third clinical trial site to be approved for this study which is currently recruiting participants in New Jersey and Texas.
  • QSAM’s study is a multiple center, open label, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in participants, and also assess early efficacy signals.
  • QSAM is dedicated to developing its Cyclosam® product for this important population, and participants with any of these bone cancer types are eligible for this clinical trial.

Global Orthopedic Oncology Treatment Market to 2030 - Players Include Stryker, Zimmer Biomet holdings, Medtronic and Amgen - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Health, Oncology, Nursing, Joint, Magnetic resonance imaging, Hand, Spine, Diagnosis, CT, MRI, Osteosarcoma, PET, Patient, Incidence, Malignancy, Bone, Medical tourism, Ascending limb of loop of Henle, Recurrence, Computer, Research, Risk, Survival, Disease, Growth, Ewing sarcoma, Cancer, Trauma, Neoplasm, Prevalence, Elective surgery, Human, Dentistry, Medical imaging, Marketing

Reconstructive surgery has the largest share in the global orthopedic oncology treatment market.

Key Points: 
  • Reconstructive surgery has the largest share in the global orthopedic oncology treatment market.
  • Moreover, growth in medical tourism in the region in the last decade has further fueled the market for orthopedic oncology treatment market in Asia-Pacific.
  • What are the key micro and macro environmental factors that are impacting the growth of Orthopedic Oncology Treatment market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Orthopedic Oncology Treatment market worldwide?